|
1.
|
|
|
2.
|
|
7.8 MB |
Desarrollo de baterías secundarias de zinc-aire con electrolitos acuosos alternativos
/
Iruin Amatriain, Elena, autor. ;
Blázquez Martín, José Alberto, supervisor acadèmic. ;
Universitat Autònoma de Barcelona.
Departament de Química.
Les bateries secundàries de zinc-aire són una tecnologia prometedora degut la seva elevada capacitat, cost reduït i baixa toxicitat. No obstant, aquesta tecnologia presenta algunes limitacions que han de ser superades per al seu desenvolupament i comercialització. [...]
Las baterías secundarias de zinc-aire son una tecnología prometedora debido a su elevada capacidad, reducido coste y baja toxicidad. Sin embargo, esta tecnología presenta ciertas limitaciones que deben ser superadas para su desarrollo y comercialización. [...]
Secondary zinc-air batteries are a promising technology due to their high capacity, reduced cost and low toxicity. However, this technology faces some problems that need to be overcome for their development and commercialization. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2020.
|
|
|
3.
|
|
10 p, 582.3 KB |
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
/
López-Corral, L. (Hematology Department. Complejo Asistencial Universitario de Salamanca-IBSAL. Centro de Investigación del Cáncer-IBMCC) ;
Caballero-Velázquez, T. (Hematology Department. Instituto de Biomedicina de Sevilla. IBiS/Hospital Universitario Virgen del Rocío/CSIC/CIBERON/Universidad de Sevilla) ;
López-Godino, O. (Hematology Department. Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación. IMIB. Universidad de Murcia) ;
Rosiñol, L. (Department of Hematology. Amyloidosis and Myeloma Unit. Hospital Clínic. IDIBAPS) ;
Pérez-Vicente, S. (Hematology Department. Instituto de Biomedicina de Sevilla. IBiS/Hospital Universitario Virgen del Rocío/CSIC/CIBERON/Universidad de Sevilla) ;
Fernandez-Avilés, F. (Department of Hematology. Amyloidosis and Myeloma Unit. Hospital Clínic. IDIBAPS) ;
Krsnik, I. (Hematology Department. Instituto de Investigación Puerta de Hierro Majadahonda) ;
Morillo, Daniel (Hematology Department. Instituto de Investigación Puerta de Hierro Majadahonda) ;
Heras, I. (Hematology Department. Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación. IMIB. Universidad de Murcia) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rifon, J.J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Sampol, A. (Hematology Department. Hospital Son Espases) ;
Iniesta, F. (Hematology Department. University Hospital of Virgen de la Arrixaca) ;
Ocio, E.M. (Hematology Department. Complejo Asistencial Universitario de Salamanca-IBSAL. Centro de Investigación del Cáncer-IBMCC) ;
Martin, J. (Hematology Department. Instituto de Biomedicina de Sevilla. IBiS/Hospital Universitario Virgen del Rocío/CSIC/CIBERON/Universidad de Sevilla) ;
Rovira Tarrats, Montserrat (Department of Hematology. Amyloidosis and Myeloma Unit. Hospital Clínic. IDIBAPS) ;
Cabero, M. (Hematology Department. Instituto de Investigación Puerta de Hierro Majadahonda) ;
Castilla-Llorente, C. (Hematology Department. Gustave Roussy Cancer Center) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torres-Juan, M. (Hematology Department. Hospital Son Espases) ;
Moraleda, J.M. (Hematology Department. University Hospital of Virgen de la Arrixaca) ;
Martinez, C. (Department of Hematology. Amyloidosis and Myeloma Unit. Hospital Clínic. IDIBAPS) ;
Vázquez, A. (Hematology Department. Instituto de Investigación Puerta de Hierro Majadahonda) ;
Gutierrez, G. (Department of Hematology. Amyloidosis and Myeloma Unit. Hospital Clínic. IDIBAPS) ;
Caballero, D. (Hematology Department. Complejo Asistencial Universitario de Salamanca-IBSAL. Centro de Investigación del Cáncer-IBMCC) ;
San Miguel, J.F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Mateos, M.V. (Hematology Department. Complejo Asistencial Universitario de Salamanca-IBSAL. Centro de Investigación del Cáncer-IBMCC) ;
Pérez-Simón, J.A. (Hematology Department. Instituto de Biomedicina de Sevilla. IBiS/Hospital Universitario Virgen del Rocío/CSIC/CIBERON/Universidad de Sevilla) ;
Universitat Autònoma de Barcelona
Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment remains challenging. [...]
2019 -  10.1016/j.bbmt.2019.04.026
Biology of Blood and Marrow Transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1703-1712
|
|
|
4.
|
|
6 p, 359.1 KB |
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma : impact of an MGUS-like signature
/
Rodríguez-Otero, P. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Mateos, M.V. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Martínez-López, J. (Hospital Universitario 12 de Octubre. Instituto de Investigación 12 de Octubre. CIBERONC) ;
Hernández, M.T. (Hospital Universitario de Canarias) ;
Ocio, E.M. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Rosiñol, L. (Hospital Clinic I Provincial. Institud'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ;
Martínez, R. (Hospital Clínico San Carlos) ;
Teruel, A.I. (Hospital Clínico de Valencia) ;
Gutiérrez, N.C. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Bargay, J. (Hospital Son Llatzer) ;
Bengoechea, E. (Hospital de Donostia) ;
González, Y. (Institut d'Oncologia Dr. Josep Trueta) ;
de Oteyza, J.P. (Hospital de Madrid Sanchinarro. Universidad CEU San Pablo) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Nuñez-Córdoba, J.M. (Research Support Service. Central Clinical Trials Unit. University Clinic of Navarra) ;
Encinas, C. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Martín, J. (Hospital General Virgen del Rocío) ;
Cabrera, C. (Hospital San Pedro de Alcántara) ;
Palomera, L. (Hospital Clínico Universitario Lozano Blesa) ;
de Arriba, F. (Servicio de Hematología y Oncología Médica. Hospital Universitario Morales Meseguer. IMIB-Arrixaca. Universidad de Murcia) ;
Cedena, M.T. (Hospital Universitario 12 de Octubre. Instituto de Investigación 12 de Octubre. CIBERONC) ;
Puig, N. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Paiva, B. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Bladé, J. (Hospital Clínico San Carlos) ;
Lahuerta, J.J. (Hospital Universitario de Canarias) ;
San Miguel, J.F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Universitat Autònoma de Barcelona
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. [...]
2019 - 10.1038/s41408-019-0176-x
Blood Cancer Journal, Vol. 9 Núm. 4 (january 2019) , p. 36
|
|
|
5.
|
|
13 p, 1.6 MB |
Pembrolizumab as consolidation strategy in patients with multiple myeloma : Results of the GEM-pembresid clinical trial
/
Puig, N. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
Corchete-Sánchez, L.A. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
Pérez-Morán, J.J. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
Dávila, J. (Complejo Asistencial de Ávila. Hematology Department) ;
Paíno, T. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
de la Rubia, J. (Hematology Service. University Hospital Peset and Internal Medicine. School of Medicine and Dentistry. Catholic University of Valencia) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín-Sánchez, J. (Hematology Department. Hospital Universitario Virgen del Rocío) ;
de Arriba, F. (Servicio de Hematología y Oncología Médica. Hospital Universitario Morales Meseguer. IMIB-Arrixaca. Universidad de Murcia) ;
Bladé, J. (Hematology Department. Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi I Sunyer) ;
Blanchard, M.J. (Hematology Department. Hospital Ramón y Cajal) ;
González-Calle, V. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
García-Sanz, R. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
Paiva, B. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Lahuerta, J.J. (Centro de Investigación Biomédica en Red Cáncer (CIBERONC). Instituto de Investigación. Hospital Universitario 12 de Octubre) ;
San-Miguel, J.F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Mateos, M.V. (Cancer Research Center (CiC-IBMCC. CSIC/USAL). Hematology Department. Center for Biomedical Research in Network of Cancer (CIBERONC). Institute of Biomedical Research of Salamanca (IBSAL). University Hospital of Salamanca) ;
Ocio, E.M. (Hospital Universitario Marqués de Valdecilla (IDIVAL). Universidad de Cantabria) ;
Universitat Autònoma de Barcelona
PD1 expression in CD4 and CD8 T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first-or second-line treatment. [...]
2020 - 10.3390/cancers12123615
Cancers, Vol. 12 Núm. 12 (december 2020) , p. 1-13
|
|
|
6.
|
|
17 p, 3.1 MB |
Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci
/
Li, Tianlu (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Fernández, L. (Instituto de Parasitología y Biomedicina López-Neyra. Consejo Superior de Investigaciones Científicas (IPBLN-CSIC)) ;
Andrés-León, E. (Instituto de Parasitología y Biomedicina López-Neyra. Consejo Superior de Investigaciones Científicas (IPBLN-CSIC)) ;
Ciudad, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Javierre, BM (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
López-Isac, E. (Instituto de Parasitología y Biomedicina López-Neyra. Consejo Superior de Investigaciones Científicas (IPBLN-CSIC)) ;
Guillén-Del-Castillo, A. (Hospital Universitari Vall d'Hebron) ;
Simeón-Aznar, C.P. (Hospital Universitari Vall d'Hebron) ;
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martin, J. (Instituto de Parasitología y Biomedicina López-Neyra. Consejo Superior de Investigaciones Científicas (IPBLN-CSIC)) ;
Universitat Autònoma de Barcelona
Background: Systemic sclerosis (SSc) is a genetically complex autoimmune disease mediated by the interplay between genetic and epigenetic factors in a multitude of immune cells, with CD4+ T lymphocytes as one of the principle drivers of pathogenesis. [...]
2020 - 10.1186/s13073-020-00779-6
Genome Medicine, Vol. 12 Núm. 1 (25 2020) , p. 81
|
|
|
7.
|
|
13 p, 1.0 MB |
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : A comparative study of the ALWP EBMT
/
Sanz, Jaime (CIBERONC. Instituto Carlos III) ;
Galimard, J.E. (EBMT Paris Office. Hospital Saint Antoine) ;
Labopin, M. (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Afanasyev, B. (First State Pavlov Medical University of St. Petersburg. Raisa Gorbacheva Mem. Research Institute for Paediatric Oncology. Hematology. and Transplantation) ;
Angelucci, E. (Department of Haematology. IRCCS Ospedale Policlinico San Martino) ;
Ciceri, F. (Haematology and BMT) ;
Blaise, D. (Programme de Transplantation and Therapie Cellulaire. Centre de Recherche en Cancérologie de Marseille. Institut Paoli Calmettes) ;
Cornelissen, J.J. (Department of Hematology. Erasmus MC Cancer Institute. University Medical Center Rotterdam) ;
Meijer, E. (Department of Hematology (Br 250). VU University Medical Center) ;
Diez-Martin, J.L. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Koc, Y. (Stem Cell Transplant Unit. Medical Park Hospitals) ;
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castagna, L. (Transplantation Unit. Department of Oncology and Haematology. Istituto Clinico Humanitas) ;
Savani, B. (Vanderbilt University Medical Center) ;
Ruggeri, A. (Department of Pediatric Hematology and Oncology. IRCCS Bambino Gesù Children's Hospital) ;
Nagler, A. (ALWP of the EBMT Office. Saint Antoine Hospital) ;
Mohty, M. (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Universitat Autònoma de Barcelona
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. [...]
2020 - 10.1186/s13045-020-00882-6
Journal of hematology & oncology, Vol. 13 Núm. 1 (june 2020) , p. 46
|
|
|
8.
|
|
16 p, 1.4 MB |
Sampling time-dependent artifacts in single-cell genomics studies
/
Massoni-Badosa, R. (CNAG-CRG. Centre for Genomic Regulation (CRG). Barcelona Institute of Science and Technology (BIST)) ;
Iacono, G. (CNAG-CRG. Centre for Genomic Regulation (CRG). Barcelona Institute of Science and Technology (BIST)) ;
Moutinho, C. (CNAG-CRG. Centre for Genomic Regulation (CRG). Barcelona Institute of Science and Technology (BIST)) ;
Kulis, M. (Institute of Biomedical Research August Pi i Sunyer (IDIBAPS)) ;
Palau, N. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marchese, D. (CNAG-CRG. Centre for Genomic Regulation (CRG). Barcelona Institute of Science and Technology (BIST)) ;
Rodríguez-Ubreva, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ballestar, E. (Hematopathology Unit. Hospital Clinic of Barcelona) ;
Rodriguez-Esteban, G. (CNAG-CRG. Centre for Genomic Regulation (CRG). Barcelona Institute of Science and Technology (BIST)) ;
Marsal, S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Aymerich, M. (Hematopathology Unit. Hospital Clinic of Barcelona) ;
Colomer, D. (Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)) ;
Campo, E. (Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)) ;
Julià, A. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martín-Subero, J.I. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Universitat Autònoma de Barcelona
Robust protocols and automation now enable large-scale single-cell RNA and ATAC sequencing experiments and their application on biobank and clinical cohorts. However, technical biases introduced during sample acquisition can hinder solid, reproducible results, and a systematic benchmarking is required before entering large-scale data production. [...]
2020 - 10.1186/s13059-020-02032-0
Genome biology, Vol. 21 Núm. 1 (november 2020) , p. 112
|
|
|
9.
|
|
8 p, 354.8 KB |
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
/
Hajek, R. (Faculty of Medicine. University of Ostrava) ;
Pour, L. (University Hospital Brno) ;
Ozcan, M. (Ankara University School of Medicine) ;
Martin Sánchez, J. (Hospital Universitario Virgen del Rocio) ;
García Sanz, R. (University Hospital of Salamanca) ;
Anagnostopoulos, A. (General Hospital of Thessaloniki "G. Papanikolaou,") ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cascavilla, N. (IRCCS "Casa Sollievo della Sofferenza" Hospital) ;
Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ;
Briso, E.M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Špička, I. (1st Department of Medicine - Department of Hematology. First Faculty of Medicine. Charles University and General Hospital in Prague) ;
Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
